pennews
www.pennews.net
Alembic Pharma gets USFDA nod for Dorzolamide Hydrochloride Ophthalmic Solution USP, 2pc
Business

Alembic Pharma gets USFDA nod for Dorzolamide Hydrochloride Ophthalmic Solution USP, 2pc

Agency News

Mumbai Aug 13 : Pharma Major, Alembic Pharmaceuticals said it has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Dorzolamide Hydrochloride Ophthalmic Solution USP, 2 pc.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Trusopt Ophthalmic Solution, 2 pc, of Merck Sharp & Dohme Corp.

Dorzolamide Hydrochloride Ophthalmic Solution is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Dorzolamide Hydrochloride Ophthalmic Solution USP, 2 pc has an estimated market size of USD 35 million for twelve months ending December 2018 according to IQVIA, the company said in a filing with BSE.

Alembic now has a total of 101 ANDA approvals (89 final approvals and 12 tentative approvals) from USFDA. (UNI)